PRCT Share Price Performance
US$29.53
-66.95 (-69.39%)
43.3% undervalued intrinsic discount
US$52.10
Fair Value
Price US$29.53
AnalystConsensusTarget US$52.10
AnalystLowTarget US$51.00
AnalystHighTarget US$87.50
Fair ValueUS$52.10
Share Pricen/a
PROCEPT BioRobotics Corporation Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 28 Fair Values set on narratives written by author
PRCT Community Narratives
AN
Fair Value US$52.1 43.3% undervalued intrinsic discount
PRCT: Share Price Will Likely React Sharply To Upcoming Earnings Data
0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
Fair Value US$51 42.1% undervalued intrinsic discount
Competitive Pressures Will Hinder Urologic Procedures Yet Spur Progress
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$85 65.3% undervalued intrinsic discount
Aging Population And Robotic Advances Will Unlock Urologic Potential
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
PRCT: Share Price Will Likely React Sharply To Upcoming Earnings Data
Key Takeaways Expanded reimbursement and increased adoption promise accelerated revenue growth and margin expansion, as Aquablation becomes a standard for minimally invasive therapy in more hospitals. International growth, successful clinical trials, and new approvals are unlocking additional long-term revenue streams and expanding market reach for sustained profitability.Read more
0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AN
US$52.1
43.3% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
25.62% p.a.
Profit Margin
13.38%
Future PE
48.4x
Price in 2028
US$65.07
Aging Population And Robotic Advances Will Unlock Urologic Potential
Key Takeaways Accelerated adoption, streamlined reimbursement, and demographic trends are expected to drive stronger-than-expected revenue growth, operating leverage, and recurring handpiece demand. Expansion into new procedure categories and global markets, backed by clinical trials, strong cash reserves, and experienced leadership, positions the company for substantial long-term upside.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$85
65.3% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
31.4% p.a.
Profit Margin
12.32%
Future PE
91.96x
Price in 2028
US$104.84
Competitive Pressures Will Hinder Urologic Procedures Yet Spur Progress
Key Takeaways Growth potential driven by demographic trends and innovation faces threats from competition, pricing pressure, and possible market shifts to non-device treatments. Expansion and recurring revenue are promising, but high costs, reimbursement risks, and geopolitical factors could constrain margins and profitability.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$51
42.1% undervalued intrinsic discount
AnalystLowTarget Fair Value
Revenue
26.89% p.a.
Profit Margin
12.49%
Future PE
60.58x
Price in 2028
US$63.03
Trending Discussion
Recently Updated Narratives
AN
PRCT: Stock Reaction Will Recover As Guidance Proves Conservative
Fair Value: US$52.1 43.3% undervalued intrinsic discount
18 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Competitive Pressures Will Hinder Urologic Procedures Yet Spur Progress
Fair Value: US$51 42.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Population And Robotic Advances Will Unlock Urologic Potential
Fair Value: US$85 65.3% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
PROCEPT BioRobotics Corporation Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -1.51
- 64.55%
- -28.20%
- 13.6%
About PRCT
- Founded
- 2007
- Employees
- 756
- CEO
- WebsiteView website
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. It also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
